These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8721904)

  • 41. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
    Smith PJ; van Dyk J; Fredericks A
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determinants of serum concentration of first-line anti-tuberculosis drugs from China.
    Lei Q; Wang H; Zhao Y; Dang L; Zhu C; Lv X; Wang H; Zhou J
    Medicine (Baltimore); 2019 Oct; 98(41):e17523. PubMed ID: 31593125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinico-laboratory diagnosis of adverse reactions in children to antitubercular drugs in different combinations].
    Kazakov KS; Zakharova RI; Absadykova FT
    Probl Tuberk; 1990; (9):40-2. PubMed ID: 2274509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
    Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
    Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
    Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
    Ellard GA; Ellard DR; Allen BW; Girling DJ; Nunn AJ; Teo SK; Tan TH; Ng HK; Chan SL
    Am Rev Respir Dis; 1986 Jun; 133(6):1076-80. PubMed ID: 3717760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid.
    Durand F; Bernuau J; Pessayre D; Samuel D; Belaiche J; Degott C; Bismuth H; Belghiti J; Erlinger S; Rueff B
    Hepatology; 1995 Apr; 21(4):929-32. PubMed ID: 7705802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Fixed drug eruption after taking ethambutol].
    Bakayoko AS; Kaloga M; Kamagate M; Kone Z; Daix AT; Ohui E; Gbery I; Domoua K
    Rev Mal Respir; 2015 Jan; 32(1):48-51. PubMed ID: 25618204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry.
    Song SH; Jun SH; Park KU; Yoon Y; Lee JH; Kim JQ; Song J
    Rapid Commun Mass Spectrom; 2007; 21(7):1331-8. PubMed ID: 17340570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis.
    Hernández-González O; Zarazúa S; Veytia-Bucheli JI; González-Chávez MM; Rodríguez-Pinal CJ; Medellín-Garibay SE; Uresti-Rivera EE; Pérez-Vázquez FJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    J Sep Sci; 2021 Jan; 44(2):521-529. PubMed ID: 33200497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy. A Hong Kong Tuberculosis Treatment Services-British Medical Research Council Investigation.
    Clin Allergy; 1974 Mar; 4(1):1-12. PubMed ID: 4824569
    [No Abstract]   [Full Text] [Related]  

  • 55. [Adverse reactions of antituberculous agents, especially about its onset and duration].
    Yamada H; Yasuoka A; Sasayama K; Doutsu Y; Hayashi T; Kohno S; Yamaguchi K; Hirota M; Hara K
    Kekkaku; 1990 Sep; 65(9):563-8. PubMed ID: 2232434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2014 Oct; 69(10):2841-7. PubMed ID: 25140577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adjusting or not adjusting isoniazid dosage?].
    Parrot R; Boval C; Grosset J; Gaillard JP
    Rev Fr Mal Respir; 1983; 11(5):705-12. PubMed ID: 6658156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distribution of three antituberculous drugs and their metabolites in different parts of pathological vertebrae with spinal tuberculosis.
    Liu P; Zhu Q; Jiang J
    Spine (Phila Pa 1976); 2011 Sep; 36(20):E1290-5. PubMed ID: 21311403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide.
    Taki H; Ogawa K; Murakami T; Nikai T
    Kekkaku; 2008 Jul; 83(7):497-501. PubMed ID: 18709966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Changes in the isoniazid inactivation index during antituberculosis treatment in children].
    Bouveret JP; Hanoteau J; Gerbeaux J; Houin G; Tillement JP
    Arch Fr Pediatr; 1983 Oct; 40(8):615-9. PubMed ID: 6606407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.